treatment only once because he didn’t like putting chemicals in his body for a treatment he felt had a low chance of
success. Landon sought out a doctor who recommended
a holistic treatment, including vitamins, carrot juice and
coffee enemas. He felt stronger on the holistic regimen and
his stomach pains subsided, but when he went back for
another CT scan on April 24, Landon learned his cancer
had doubled in size and spread elsewhere in his body in
less than three weeks.
“At that point, we were looking at him not being here, and I
think he knew,” Clerico recalls. “That was a tough day.”
The National Cancer Institute estimated that more than
53,000 people in the U.S. would be diagnosed with pancreatic cancer and more than 41,000 would die of the disease
in 2016. While pancreatic cancer accounts for just 3 percent
of all cancer cases in the U.S., it is responsible for about 7
percent of all cancer deaths. The vast majority of pancreatic
ANALYZING TUMOR TISSUE
Genomic analysis may open the door to new treatment options targeted at
specific genetic abnormalities in pancreatic tumors. Check the following
resources to join a clinical trial and contribute to research.
The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH), a clinical
trial offered through the National Cancer Institute, seeks to collect 6,000 tumor
samples and analyze them to see whether they have mutations that might
respond to targeted drugs.
Know Your Tumor, a national registry offered through the Pancreatic Cancer
Action Network (PanCAN), provides molecular profiling for eligible patients with
metastatic pancreatic cancer. PanCAN covers the costs of coordinating tumor
testing and developing the report, while the patient’s health insurance company
is billed for the biopsy, molecular tests and related costs.
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study,
offered through the American Society of Clinical Oncology, provides approved
targeted therapies to patients with advanced cancer who have had their tumor
sequenced and have not responded or have stopped responding to standard
Let’s Win, an initiative started by a stage IV pancreatic cancer survivor,
includes easy-to-digest information on clinical trials, including those that
provide genomic analysis.
RUN BRAVE in a City Near You
Professionally-Timed 5K | 1-Mile Fun Run/Walk
SPONSORED IN PART BY BENEFITING
UndyRaces_HalfPgad.indd 1 2/27/17 6:28PM